News Center

News Center

The latest clinical updates and product development news from Progenity.

Highlighting Opportunities for Technologies Aimed at Improving Diagnosis and Treatment of Gastrointestinal Disorders

This acquisition further strengthens Progenity’s existing intellectual property portfolio and development of ingestible devices designed to advance research, diagnosis, and treatment for conditions of the gastrointestinal (GI) tract.

Dr. Kotzin’s experience in the development of novel biotherapeutics, especially in autoimmune and inflammatory diseases, will provide valuable guidance as the company advances its pipeline of precision therapeutics/biotherapeutics and diagnostics.

Announcing a collaborative research and development initiative for women’s health with a focus on preterm births.

Announcing our new Senior Vice President and Chief Financial Officer (CFO).

We announced results from three studies that represent potential breakthrough systems for diagnosing, treating, and monitoring digestive diseases through ingestible technologies.

Progenity, Inc., a privately held biotechnology company developing precision medicine solutions across genomic/epigenomic, proteomic, and microbiomic diagnostic and therapeutic platforms, this week announced three upcoming poster presentations.